Similar to the unresectable setting, there has been a tremendous shift in the treatment paradigm of locoregional/resectable melanoma, where adjuvant treatment with anti-PD1 or BRAF/MEKi for the duration of one year is commonly recommended in completely resected stages 2b to 4, subject to local registration status [10,11,12,13,14,15]. Here, PDCD1 is linked to melanoma.